What's in Milestone Pharmaceuticals Inc.'s pipeline?

Milestone Pharmaceuticals Inc. has 1 drugs in our index: 0 marketed, 0 filed, 1 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Milestone Pharmaceuticals Inc.'s portfolio?

Top competitors by shared drug class: Nishtar Medical University, Zealand University Hospital.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/milestone-pharmaceuticals-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-06-10 · How we verify

Milestone Pharmaceuticals Inc. — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Milestone Pharmaceuticals Inc. pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Etripamil NS	Etripamil NS	phase 3	Calcium channel blocker (non-dihydropyridine)	L-type calcium channel	Cardiovascular

Therapeutic area mix

Cardiovascular · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Nishtar Medical University · 1 shared drug class
Zealand University Hospital · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Milestone Pharmaceuticals Inc.:

Cite this brief

Drug Landscape (2026). Milestone Pharmaceuticals Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/milestone-pharmaceuticals-inc. Accessed 2026-06-10.